Literature DB >> 2903875

Anaphylaxis to muscle relaxants: cross-sensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases.

D A Moneret-Vautrin1, J L Guéant, L Kamel, M C Laxenaire, S el Kholty, J P Nicolas.   

Abstract

Thirty-four patients (31 female and three male patients) with a previous anaphylactoid shock to muscle relaxants were investigated. The seric antimyorelaxant IgE was detected by radioimmunoassay (RIA), and the results were compared to intradermal test (IDR) reactions to dilutions of the commercial drugs. The RIA was carried out with a Sepharose-myorelaxant solid phase and anti-IgE 125I-labeled IgG. The results corresponded to the percentage of labeled anti-IgE bound on the solid phase. The RIA with Sepharose-alcuronium and Sepharose-choline was estimated positive from determination with normal sera (n = 12) when bound IgE was greater than 1.0% and 1.5%, respectively. The RIA and IDR were positive in 43.5% and 75%, respectively, of the cases, with a concordance of 66%. One test at least was positive in 79.4% of the cases. No correlation was found between IgE seric levels and the RIA nor between the cutaneous sensitivity and the RIA. Cross-reactivity with Sepharose-choline and Sepharose-alcuronium was observed in 50%, and it was demonstrated by IDR in only 34.2%. The RIA demonstrated the specificity of IgE to quaternary ammonium compounds as myorelaxant drugs. The positive IDR revealed the bridging of mast cell-bound specific IgE, depending on structural conditions, such as the flexibility of the molecules or the variable specificity of the antibodies, restricted to quaternary ammonium ions or enlarged to a broader part of the incriminated molecules.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903875     DOI: 10.1016/0091-6749(88)90074-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Prevention of anaphylactic reactions to anaesthetic drugs.

Authors:  Malcolm M Fisher; Gordon S Doig
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  Nonspecific histamine-releasing properties of general anesthetic drugs.

Authors:  G Marone; C Stellato; P Mastronardi; B Mazzarella
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

Review 3.  Allergy to muscle relaxants.

Authors:  J Birnbaum; D Vervloet
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

4.  Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.

Authors:  Chloe Tesmoingt; Olivier Lidove; Axele Reberga; Marguerite Thetis; Chloe Ackaert; Pascale Nicaise; Philippe Arnaud; Thomas Papo
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

5.  Wheal and flare responses to muscle relaxants in humans.

Authors:  J H Levy; D Adelson; B Walker
Journal:  Agents Actions       Date:  1991-11

Review 6.  Crossreactions to muscle relaxants in the operating room.

Authors:  D A Moneret-Vautrin
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 7.  Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.

Authors:  M Abel; W J Book; J B Eisenkraft
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 8.  Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis.

Authors:  Anna M Brusch; Russell C Clarke; Peter R Platt; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

9.  [Severe anaphylaxis from rocuronium].

Authors:  J C Kubitz; T Krause; R Dietz; P Friederich; A E Goetz
Journal:  Anaesthesist       Date:  2006-11       Impact factor: 1.041

Review 10.  Adverse reactions to neuromuscular blocking agents.

Authors:  Paul-Michel Mertes; Marie Claire Laxenaire
Journal:  Curr Allergy Asthma Rep       Date:  2004-01       Impact factor: 4.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.